UK Markets close in 8 hrs 28 mins

Vistin Pharma ASA (0RAM.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
11.25-9.80 (-46.56%)
As of 5:27PM BST. Market open.
Full screen
Previous close21.05
Bid0.00 x N/A
Ask0.00 x N/A
Day's range21.90 - 21.90
52-week range21.90 - 21.90
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.92
PE ratio (TTM)11.72
EPS (TTM)0.96
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Mandatory notification of trade in Vistin Pharma ASA

    Tycoon Industrier AS has on 13 September 2021 sold 784,280 shares in Vistin Pharma ASA at NOK 21.1 per share. Ferncliff Listed DAI AS has on 13 September 2021 purchased 784,280 shares in Vistin Pharma ASA at NOK 21.1 per share. The total number of shares owned by the Ferncliff group (controlled by Øystein Stray Spetalen) is unchanged after the transactions. Tycoon Industrier AS and Ferncliff Listed DAI AS are closely associated with board member Øystein Stray Spetalen. Attachments 20210913_Notif

  • Globe Newswire

    Vistin Pharma ASA: Meldepliktig handel

    Intertrade Shipping AS har i dag kjøpt 148 461 aksjer i Vistin Pharma ASA til gjennomsnittskurs 16,25 per aksje. Intertrade Shipping AS eier etter kjøpet 11 075 000 aksjer i Vistin Pharma, tilsvarende 24.9% av selskapets utestående aksjer. Intertrade Shipping AS er kontrollert av Øyvin Brøymer som er Styreformann i Vistin Pharma ASA.

  • Globe Newswire

    Vistin Pharma ASA: Third quarter and YTD 2020 financial results

    Oslo, Norway, 30 October 2020 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the third quarter and YTD 2020. The revenues for the third quarter of 2020 ended at MNOK 55 (Q3’19: MNOK 68). YTD 2020 the revenue was MNOK 189, compared to MNOK 171 in the first three quarters of 2019, a growth of 11%. Third quarter EBITDA for pharmaceuticals was MNOK 9.5 (Q3’19: MNOK 11.8), and YTD 2020 EBITDA of MNOK 44.3, compared to MNOK 23.6 in the first three quarters of 2019, an 88% increase. The net profit for the group ended at MNOK 4.5 (Q3’19: MNOK 59.6) for the third quarter of 2020. For first three quarters of 2020 the net loss was MNOK 105.6, compared to a profit of MNOK 59.6 YTD 2019. The net loss in 2020 is driven by the closing of the oil derivative portfolio in March. Vistin Pharma had cash of MNOK 97.5 (Q3’19 MNOK: 305) as of 30 September 2020. First installment of 15% for the Metformin Expansion Project (MEP) was paid in September. The company has a strong balance sheet with an equity ratio of 83% and no interest-bearing debt.   The third quarter conference call, which will be held today, 30 October, at 8.30am (CET) and will be available via web and audio through the following access points: Telephone conference:Confirmation Code:........ 9184755International Dial-In:........ +44 (0) 2071 928338Norway, Oslo:................ +47 21563015United States, New York: +1 6467413167 Webcast: The conference call will be held in Norwegian.        Please find the Q3 report and presentation enclosed. The report will also be made available on ***** For further information, please contact: Kjell-Erik NordbyCEO+47 91 36 42 Alexander KarlsenCFO+47 97 05 36 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.   Attachments Vistin Pharma ASA third quarter presentation 2020 Vistin Pharma ASA third quarter report 2020